3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia
34
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Lymphoma
27
Burkitt Lymphoma
27
Lymphoma, Non-Hodgkin
22
Lymphoma, Large B-Cell, Diffuse
22
Myelodysplastic Syndromes
20
Leukemia, Myeloid, Chronic-Phase
20
Lymphoma, Follicular
19
Leukemia, Lymphocytic, Chronic, B-Cell
18
Leukemia, Myeloid, Accelerated Phase
17
Multiple Myeloma
16
Lymphoma, Large-Cell, Immunoblastic
15
Blast Crisis
15
Myeloproliferative Disorders
14
Leukemia, Myeloid, Acute
14
Dendritic Cell Sarcoma, Interdigitating
14
Recurrence
13
Lymphoma, Mantle-Cell
13
Lymphoma, B-Cell, Marginal Zone
13
Graft vs Host Disease
13
Leukemia, Myelomonocytic, Chronic
12
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
12
Hodgkin Disease
11
Congenital Abnormalities
11
Neoplasms, Plasma Cell
10
Myelodysplastic-Myeloproliferative Diseases
10
Anemia, Refractory, with Excess of Blasts
9
Primary Myelofibrosis
8
Lymphoma, Large-Cell, Anaplastic
8
Interventions
Mycophenolic Acid
2
vedolizumab
1
Ursodeoxycholic Acid
1
Steroids
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hepatitis
×
Methylprednisolone
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled